Open AccessGraves’ orbitopathy after allogeneic bone marrow transplantation in a patient with Fanconi anemia – side effect of alemtuzumab therapy?
Author(s) -
Cima Luminita Nicoleta,
Lambrescu Ioana Maria,
Stejereanu Lavinia,
Colita Anca,
Or Reuven,
Fica Simona
Publication year - 2018
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.1486
Subject(s) - medicine , alemtuzumab , fanconi anemia , multiple sclerosis , hematopoietic stem cell transplantation , transplantation , anemia , thyroid , surgery , immunology , biochemistry , chemistry , dna repair , gene
Key Clinical Message A few cases of thyroid eye disease following alemtuzumab therapy have been described in patients with multiple sclerosis. Our patient is the first case of Graves’ orbitopathy after alemtuzumab conditioning for hematopoietic stem cell transplantation.